- Home
- RBBN vs TSHA Comparison
RBBN vs TSHA Comparison
Compare RBBN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBBN
- TSHA
- Stock Information
- Founded
- RBBN 1997
- TSHA 2019
- Country
- RBBN United States
- TSHA United States
- Employees
- RBBN N/A
- TSHA N/A
- Industry
- RBBN EDP Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- RBBN Technology
- TSHA Health Care
- Exchange
- RBBN Nasdaq
- TSHA Nasdaq
- Market Cap
- RBBN 662.0M
- TSHA 728.4M
- IPO Year
- RBBN 2000
- TSHA 2020
- Fundamental
- Price
- RBBN $4.07
- TSHA $2.54
- Analyst Decision
- RBBN Strong Buy
- TSHA Strong Buy
- Analyst Count
- RBBN 4
- TSHA 5
- Target Price
- RBBN $5.88
- TSHA $8.20
- AVG Volume (30 Days)
- RBBN 530.3K
- TSHA 3.1M
- Earning Date
- RBBN 07-23-2025
- TSHA 08-11-2025
- Dividend Yield
- RBBN N/A
- TSHA N/A
- EPS Growth
- RBBN N/A
- TSHA N/A
- EPS
- RBBN N/A
- TSHA N/A
- Revenue
- RBBN $835,496,000.00
- TSHA $7,224,000.00
- Revenue This Year
- RBBN $7.27
- TSHA N/A
- Revenue Next Year
- RBBN $5.32
- TSHA N/A
- P/E Ratio
- RBBN N/A
- TSHA N/A
- Revenue Growth
- RBBN 1.91
- TSHA N/A
- 52 Week Low
- RBBN $2.75
- TSHA $1.05
- 52 Week High
- RBBN $5.38
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- RBBN 58.86
- TSHA 53.68
- Support Level
- RBBN $4.03
- TSHA $2.33
- Resistance Level
- RBBN $4.24
- TSHA $2.51
- Average True Range (ATR)
- RBBN 0.13
- TSHA 0.15
- MACD
- RBBN -0.00
- TSHA -0.01
- Stochastic Oscillator
- RBBN 68.89
- TSHA 74.36
About RBBN Ribbon Communications Inc.
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.